Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lestaurtinib - Teva Pharmaceuticals

Next Previous
Drug Profile

Lestaurtinib - Teva Pharmaceuticals

Alternative Names: CEP-701; KT 5555; SPM 924

Latest Information Update: 09 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko
  • Developer Cephalon; Children's Oncology Group; Icahn School of Medicine at Mount Sinai; Kyowa Hakko; National Cancer Institute (USA); Teva Pharmaceutical Industries
  • Class Antineoplastics; Antipsoriatics; Antithrombotics; Carbazoles; Indoles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Multiple myeloma; Myelofibrosis; Pancreatic cancer; Plaque psoriasis; Polycythaemia vera; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Thrombocytosis

Most Recent Events

  • 25 Jan 2018 Lestaurtinib is still in phase III trials for Acute lymphoblastic leukaemia (Combination therapy, In infants, Newly diagnosed) in USA, New Zealand, Canada and Australia (PO) (NCT00557193)
  • 04 Sep 2015 Phase-II development for Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy), Myelofibrosis, Polycythaemia vera and Thrombocytosis is ongoing in USA
  • 04 Sep 2015 No recent reports on development identified - Phase-II for Acute myeloid leukaemia (Second-line therapy or greater) in Ukraine, Sweden, Spain, Australia, Canada, Germany, Israel, Italy, New Zealand, Poland, Romania and Russia (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top